The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2010MicroRNAs as Biomarkers for Parkinson's Disease; A Comparison of CSF and Blood
Objective/Rationale:
We, and many other groups, hypothesize that miRNAs have the potential to be selective and sensitive diagnostic indicators for Parkinson’s disease. The focus of this project is to... -
Rapid Response Innovation Awards, 2010The Role of Alpha-synuclein in the Pathogenesis of Parkinson's Disease in a Pre-clinical Model
Objective/Rationale:
We hypothesized that alpha-synuclein increased level and accumulation within the target neurons in the affected model acts as a trigger mechanism for activation of additional... -
Target Validation, 2010Validation of FKBP Inhibitors to Target Alpha-synuclein Pathology in Pre-clinical Model Brain
Objective/Rationale:
FK506 Binding Proteins (FKBPs) are enzymes that play a role in protein folding. FKBPs are highly expressed in human brain and are thought to be involved in neurodegenerative... -
Therapeutics Development Initiative, 2010Evaluation of the Neuroprotectivity Ability of Zymes' Water-soluble CoQ10 (WS-CoQ10) in Pre-clinical Models of PD; Preclinical Validation and Dose Optimization for Clinical Study
Objective/Rationale:
Coenzyme Q10 is a lipid soluble naturally occurring compound essential for energy production and defence against oxidative stress. Recent clinical studies indicate that it may... -
Alpha-Synuclein Therapeutics, 2010Use of the Orally Administered Pharmacological Chaperone AT3375 to Reduce Alpha-synuclein Levels in the Brain of Thy-1 Alpha-synuclein Small Models
Objective/Rationale:
Mutations in the GBA1 gene increase the risk of Parkinson’s. These mutations reduce the activity of the enzyme glucocerebrosidase (GCase), which is deficient in the lysosomal... -
Target Validation, 2010Kynurenine 3-monooxygenase (KMO) as a Target to Develop Drugs to Block Progression of Parkinson's Disease
Objective/Rationale:
These studies will validate the enzyme kynurenine 3-monooxygenase (KMO) as a target to develop drugs to treat PD (PD). KMO is expressed in cells involved in inflammation, which is...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.